A

Australian Alzheimer's Research Foundation | Clinical Trials Division

Research site
(Unclaimed)
Location
Suite 17, 95 Monash Avenue, Nedlands, Western Australia, Australia
Site insights

Top conditions

Alzheimer Disease (18 trials)

Dementia (5 trials)

Cognitive Dysfunction (2 trials)

Mental Disorders (1 trial)

Brain Diseases (1 trial)

Top treatments

Gantenerumab
Aducanumab
LY3314814
Lanabecestat
Lecanemab
Deferiprone
221AD302
CT1812
221AD301
Simufilam

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 18
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration includ...

Enrolling
Alzheimer Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: Placebo
Drug: JNJ-63733657

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discont...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adul...

Active, not recruiting
Mild to Moderate Alzheimer's Disease
Drug: CT1812
Drug: Placebo

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab
Drug: Placebo

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting
Alzheimer Disease
Drug: Simufilam
Drug: Placebo

Trial sponsors

Roche logo

Roche (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems